Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemotherapy regimens

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    787 result(s) found for: Chemotherapy regimens. Displaying page 1 of 40.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-001150-27 Sponsor Protocol Number: 2006/01 Start Date*: 2006-09-11
    Sponsor Name:University Hospital Gent
    Full Title: Sandostatin LAR in prevention of Chemotherapy Induced Diarrhea
    Medical condition: Chemo-Therapy Induced Diarrhea
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020660-37 Sponsor Protocol Number: CR3294-2-01 Start Date*: 2010-09-08
    Sponsor Name:ROTTAPHARM S.P.A.
    Full Title: A Multicenter, randomized, double blind, double dummy, placebo controlled, parallel group, phase II study on the prevention of mucositis by CR3294, orally administered for 5 days in haematological ...
    Medical condition: assessment of the effect of CR3294 in preventing oral mucositis induced by conditioning myeloablative regimens in patients undergoing high-dose chemotherapy (HDCT) and autologous HSCT.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028130 LLT
    9.1 10017981 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000686-19 Sponsor Protocol Number: MO05/6844 Start Date*: 2005-04-28
    Sponsor Name:University of Leeds
    Full Title: PACT (Patient Preferences in Adjuvant Colorectal Cancer Therapy) - A randomised crossover clinical trial comparing Bolus Fluorouracil/Leucovorin to Capecitabine as treatment for moderate to high ri...
    Medical condition: Moderate to high risk resected colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000515-24 Sponsor Protocol Number: RG_17-247 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Birmingham
    Full Title: FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma
    Medical condition: Rhabdomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) NO (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DK (Trial now transitioned) SI (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004473-16 Sponsor Protocol Number: SL001-2.0 Start Date*: 2016-07-19
    Sponsor Name:Masarykův onkologický ústav
    Full Title: Prospective study investigating efficacy of lanreotide on decrease of chemotherapy induced diarrhoea (CID) in patiens with colorectal carcinoma.
    Medical condition: Chemotherapy induced diarrhoea that is resistant to common treatment including loperamide in patients with colorectal carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002602-52 Sponsor Protocol Number: BAY80-6946/16349 Start Date*: 2012-10-19
    Sponsor Name:Bayer AG
    Full Title: Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas
    Medical condition: Patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas or patients with follicular lymphoma relapsed after or refractory to standard therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    20.0 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    20.0 100000004851 10029608 Non-Hodgkin's lymphomas unspecified histology aggressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) SE (Completed) PL (Completed) AT (Completed) PT (Completed) HU (Completed) DK (Prematurely Ended) IE (Completed) GR (Completed) LU (Completed)
    Trial results: View results
    EudraCT Number: 2004-000564-28 Sponsor Protocol Number: MO18109 Start Date*: 2004-11-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An expanded access program of Tarceva (erlotinib) in patients with advanced stage IIIB/ IV non-small cell lung cancer (NSCLC)
    Medical condition: advanced stage IIIB/ IV non-small cell lung cancer (NSCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) SE (Completed) LV (Completed) AT (Completed) HU (Completed) LT (Completed) IE (Completed) CZ (Completed) IT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000259-99 Sponsor Protocol Number: RG_13-277 Start Date*: 2014-08-29
    Sponsor Name:University of Birmingham
    Full Title: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
    Medical condition: Recurrent and refractory Ewing sarcoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015567 Ewing's tumor localized LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015763 Extra-osseous Ewing's sarcoma NOS LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015566 Ewing's tumor LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015762 Extra-osseous Ewing's sarcoma non-metastatic LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015761 Extra-osseous Ewing's sarcoma metastatic PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015569 Ewing's tumor recurrent LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015568 Ewing's tumor metastatic LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058252 Ewing's tumour recurrent LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058253 Ewing's tumour metastatic LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058254 Ewing's tumour localised LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015564 Ewing's sarcoma recurrent PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015759 Extra-osseous Ewing's sarcoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015764 Extra-osseous Ewing's sarcoma recurrent PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015570 Ewing's tumour LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015562 Ewing's sarcoma metastatic PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015563 Ewing's sarcoma NOS LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) FI (Trial now transitioned) DK (Trial now transitioned) DE (Ongoing) HU (Completed) CZ (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) PL (Completed) IT (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003669-36 Sponsor Protocol Number: MS100070_0119 Start Date*: 2022-09-13
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with L...
    Medical condition: Advanced or metastatic urothelial carcinoma whose disease did not progress with 1L platinum-containing chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) ES (Trial now transitioned) FR (Trial now transitioned) DK (Completed) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020147-12 Sponsor Protocol Number: B1931008 Start Date*: 2011-02-16
    Sponsor Name:Pfizer Inc
    Full Title: AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR’S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTOR...
    Medical condition: Aggressive Non-Hodgkin Lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) ES (Completed) DE (Completed) GB (Completed) HU (Completed) LT (Completed) BG (Completed) BE (Completed) GR (Completed) NL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2016-002349-50 Sponsor Protocol Number: M16TGA Start Date*: 2017-09-29
    Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital (NKI-AVL)
    Full Title: Phase I/II study with galunisertib (LY2157299) combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer and an activated TGF-β signature
    Medical condition: colorectal carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001020-20 Sponsor Protocol Number: NKV101983 Start Date*: 2005-01-25
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title:
    Medical condition: Chemotherapy Induced Nausea and Vomiting (CINV) 0 Moderately Emetogenic Chemotherapy (MEC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IE (Completed) SK (Completed) HU (Completed) AT (Completed) GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005068-29 Sponsor Protocol Number: C2006-01 Start Date*: Information not available in EudraCT
    Sponsor Name:A.P. Pharma, Inc.
    Full Title: A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi® for the Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea a...
    Medical condition: Chemotherapy Induced Nausea and Vomiting
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054133 Prophylaxis of nausea and vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002417-36 Sponsor Protocol Number: CAPTEM Start Date*: 2014-08-28
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: An open-label, randomized, multicenter, phase II trial designed to estimate the activity of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after fi...
    Medical condition: colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10008442 Chemotherapies HLT
    17.0 100000004867 10069759 KRAS mutation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002564-69 Sponsor Protocol Number: 410/56 Start Date*: 2014-04-11
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
    Full Title: Double-blind, placebo-controlled multicenter phase II trial to evaluate the efficacy and safety of romiplostim for the treatment of chemotherapy-induced thrombocytopenia in subjects with relapse...
    Medical condition: Patients with relapsed ovarian cancer (2nd and 3rd line) treated with chemotherapy according to AGO guidelines who develop thrombocytopenia grade 3 and/or grade 4.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000378-61 Sponsor Protocol Number: AVF3694g Start Date*: 2006-05-25
    Sponsor Name:Genentech
    Full Title: ENSAYO CLINICO DE FASE III MULTICÉNTRICO, RANDOMIZADO, CONTROLADO CON PLACEBO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE BEVACIZUMAB EN COMBINACIÓN CON DIVERSOS REGÍMENES DE QUIMIOTERAPIA EN PACIENTE...
    Medical condition: Cáncer de mama metastásico Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) NL (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000741-46 Sponsor Protocol Number: 2017/2523 Start Date*: 2017-10-06
    Sponsor Name:Gustave Roussy
    Full Title: RANDOMIZED PHASE 2 TRIAL OF TWO CHEMOTHERAPY REGIMENS PLUS OR MINUS BEVACIZUMAB IN PATIENTS WITH WELL DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS
    Medical condition: Pancreatic well differentiated neuroendocrine tumors (NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005294-30 Sponsor Protocol Number: WSA-CS-002 Start Date*: 2006-05-10
    Sponsor Name:Basilea Pharmaceutica Ltd.
    Full Title: Open-label, multi-center, sequential group, clinical study to determine the safety and efficacy of escalating dosing regimens of intravenous or oral BAL8557 in the prophylaxis of patients undergoin...
    Medical condition: Neutropenic patients over 18 years with acute myeloid leukemia (AML).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005688-18 Sponsor Protocol Number: Paw1 Start Date*: 2016-05-25
    Sponsor Name:Department of Hematology, Aalborg University Hospital
    Full Title: A randomized controlled trial of alendronate as preventive treatment against the development of gluco-corticoid-induced osteoporosis in patients being treated for malignant lymphoma
    Medical condition: Age ≥ 18 years. Patients with new diagnosis or recurrence of lymphoma, which is expected to be treated with one of the listed chemotherapy regimens. Expected lifespan ≥2 years
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10025315 Lymphoma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000266-11 Sponsor Protocol Number: 2012-772 Start Date*: 2014-05-27
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer.
    Medical condition: Vulnerable elderly women with newly diagnosed stage III-IV ovarian cancer after an initial debulking surgery or with a planned interval debulking surgery.
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed) IE (Completed) DK (Prematurely Ended) FI (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 15:43:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA